Latest On KalVista Pharmaceuticals, Inc (KALV):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-03-09 18:30 EST | News | KalVista Pharmaceticals GAAP EPS of -$0.75 beats by $0.26 | N/A |  |
| 2023-02-14 10:17 EST | News | KalVista stock rises on regulatory guidance for hereditary angioedema therapy | N/A | |
| 2023-01-25 18:21 EST | News | KalVista Pharmaceuticals: The Share Price Rally Requires An Adjustment Of My Investment Thesis | N/A | |
| 2022-12-27 23:34 EST | News | KalVista stock rises ~20% on $58M stock, warrants offering | N/A | |
| 2022-12-27 08:25 EST | News | KalVista stock dips on $58M stock, warrants offering | N/A | |
About KalVista Pharmaceuticals, Inc (KALV):
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
General
- Name KalVista Pharmaceuticals, Inc
- Symbol KALV
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 56
- Last Split Factor1:14
- Last Split Date2016-11-22
- Fiscal Year EndApril
- IPO Date2015-04-09
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.kalvista.com
Valuation
- Price/Sales (Trailing 12 Mt.) 152.05
- Price/Book (Most Recent Quarter) 13.49
- Enterprise Value Revenue 137.27
Financials
- Most Recent Quarter 2021-01-31
- Current Year EPS Estimate -$2.27
- Next Year EPS Estimate -$2.86
- Operating Margin -1277%
- Return on Assets -36%
- Return on Equity -51%
- Revenue 3.82 million
- Earnings Per Share -$1.38
- Revenue Per Share $0.21
- Gross Profit -27504000
- Quarterly Earnings Growth 30.7%
Highlights
- Market Capitalization 868.78 million
- EBITDA -31926000
- PE Ratio -15.23
- Analyst Target Price $55.43
- Book Value Per Share $3.25
Share Statistics
- Shares Outstanding 24.12 million
- Shares Float 21.27 million
- % Held by Insiders 906%
- % Held by Institutions 96.23%
- Shares Short 782353
- Shares Short Prior Month 641079
- Short Ratio 0.34
- Short % of Float 4%
- Short % of Shares Outstanding 3%
Technicals
- Beta 2.17
- 52 Week High $43.08
- 52 Week Low $5.63
- 50 Day Moving Average 29.76
- 200 Day Moving Average 19.69
Dividends
- Dividend Date 2016-11-22
- ExDividend Date N/A
- Dividend Yield 0%
KalVista Pharmaceuticals, Inc (KALV) Dividend Calendar:
KALV's last dividend payment was made to shareholders on November 22, 2016.
KalVista Pharmaceuticals, Inc (KALV) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
KalVista Pharmaceuticals, Inc (KALV) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
KalVista Pharmaceuticals, Inc (KALV) Chart:
KalVista Pharmaceuticals, Inc (KALV) News:
Below you will find a list of latest news for KalVista Pharmaceuticals, Inc (KALV) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
KalVista Pharmaceuticals, Inc (KALV) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest KALV Trades:
KalVista Pharmaceuticals, Inc (KALV) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-02 | 8-K (Current report) | |
| 2020-09-14 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-09-14 | 8-K (Current report) | |
| 2020-08-25 | DEF 14A (Other definitive proxy statements) | |
KalVista Pharmaceuticals, Inc (KALV) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of KalVista Pharmaceuticals, Inc (KALV). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 906%
Institutional Ownership: 9623%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-02 | Edward P. Feener | Chief Scientific Officer | Sell | 6,000.00 | 17.14 | 102,811.80 | 72,734.00 | |
| 2020-10-30 | Albert Cha | Director | Buy | 68,255.00 | 17.17 | 1,171,808.67 | 1,090,748.00 | |
| 2020-10-30 | Albert Cha | Director | Buy | 47,431.00 | 17.34 | 822,259.07 | 1,138,179.00 | |
| 2020-10-29 | Christopher Yea | Chief Development Officer | Sell | 5,000.00 | 17.48 | 87,394.00 | 62,969.00 | |
| 2020-10-21 | Thomas Andrew Crockett | CEO | Sell | 3,693.00 | 19.01 | 70,193.59 | 195,420.00 | |
| 2020-10-21 | Thomas Andrew Crockett | CEO | Sell | 13,052.00 | 18.51 | 241,640.81 | 199,113.00 | |
| 2020-10-21 | Thomas Andrew Crockett | CEO | Sell | 5,800.00 | 17.48 | 101,412.42 | 212,165.00 | |
| 2020-10-21 | Christopher Yea | Chief Development Officer | Sell | 2,544.00 | 19.02 | 48,388.66 | 67,969.00 | |
| 2020-10-21 | Christopher Yea | Chief Development Officer | Sell | 3,500.00 | 17.68 | 61,892.95 | 70,513.00 | |
| 2020-10-21 | Edward P. Feener | Chief Scientific Officer | Sell | 5,407.00 | 18.75 | 101,374.22 | 78,734.00 | |
| 2020-10-21 | Edward P. Feener | Chief Scientific Officer | Sell | 3,600.00 | 17.65 | 63,554.04 | 84,141.00 | |
| 2020-10-20 | Thomas Andrew Crockett | CEO | Sell | 4,776.00 | 18.01 | 85,991.88 | 217,965.00 | |
| 2020-10-20 | Thomas Andrew Crockett | CEO | Sell | 11,218.00 | 17.27 | 193,786.46 | 222,741.00 | |
| 2020-10-20 | Christopher Yea | Chief Development Officer | Sell | 2,302.00 | 18.01 | 41,466.62 | 74,013.00 | |
| 2020-10-20 | Christopher Yea | Chief Development Officer | Sell | 5,640.00 | 17.27 | 97,419.16 | 76,315.00 | |
| 2020-10-20 | Edward P. Feener | Chief Scientific Officer | Sell | 2,300.00 | 18.00 | 41,406.90 | 87,741.00 | |
| 2020-10-20 | Edward P. Feener | Chief Scientific Officer | Sell | 5,600.00 | 17.26 | 96,683.44 | 90,041.00 | |
| 2020-10-16 | Thomas Andrew Crockett | CEO | Sell | 1,261.00 | 17.01 | 21,444.06 | 236,959.00 | |
| 2020-10-16 | Christopher Yea | Chief Development Officer | Sell | 914.00 | 17.00 | 15,539.28 | 81,955.00 | |
| 2020-10-16 | Edward P. Feener | Chief Scientific Officer | Sell | 993.00 | 17.00 | 16,881.00 | 95,641.00 | |